China Licensing Deals Tracker: Jan 2021
储旻华·5月以前
PharmaDJ

China Licensing Deals Tracker: Jan 2021


Writer: Minhua Chu

Editor: Howard Fields


China's biopharmaceutical industry completed a dozen licensing deals in the first month of 2021, continuing its 2020 trend of cross-the-border hot licensing deals.


Among the 11 deals, nine were in the field of oncology. The other two were late-stage assets for COVID-19 vaccine and immunology diseases licensed by Advaccine and Zai Lab, respectively.


Zai Lab (NASDAQ: ZLAB, SEHK: 9688.HK) is one of most active China biopharmas in licensing, having acquired two projects in January: efgartigimod, a first-in-class investigational antibody fragment to target the neonatal Fc receptor (FcRn), developed by the Dutch pharmaceutical firm Argenx, and TPX-0022, an orally bioavailable multi-targeted kinase inhibitor (MET, CSF1R, and SRC), by Turning Point Therapeutics.


Beigene (NASDAQ: BGNE, SEHK: 6160.HK), which recently submitted a prospectus for the Shanghai Stock Exchange (SSE) STAR Market, also announced two licensing deals. It reached a collaboration and license agreement with Novartis for its anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, some European countries, and Japan. The deal also was the top licensing deal in January. Meanwhile, Beigene got two preclinical messenger RNA (mRNA) therapies from Strand Therapeutics.


微信图片_20210221133414.png

文章关键字: China licensing deals
43982
谁阅读了此文章?
回复评论0
登录后回复评论,不超过1024个字(当前剩余字数:1024)
储旻华 个人用户

热衷收罗医药圈从研发到上市的各种“八卦”,然后基于事实和数据加以分析

联系方式

联系电话

电子邮箱

chu.minhua@pharmadj.com

公司名称

研发客

公司网站

公司地址

进入主页
Copyright © 2016-2021 研发客.All Rights Reserved.   建议反馈: Support@PharmaDJ.com   备案/许可证编号:沪ICP备17054709号-1   联系电话:021 - 88194359
关于研发客 | 加入会员 | 联系我们| 知识产权声明